The ADHD portfolio is accelerating (JORNAY PM +24%, AZSTARYS ramping) but the pain portfolio decline is accelerating too (Nucynta -44%). With guidance reaffirmed, the key swing factor is whether AZSTARYS can sustain its growth trajectory into Q4 and whether the pain portfolio erosion stabilizes. Monitor Q4 revenue mix and any guidance update at upcoming investor conferences.
Drug in focus
COLL drug pipeline →Nucynta ER
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already on the market — approved since 2008 (IR) and 2011 (ER)
- Next catalyst
- None dated
What to watchNucynta ER itself is not a catalyst for COLL. The stock's next binary event is Q3 2026 earnings on November 5, 2026, where the market will focus on guidance for the integrated portfolio including the AZSTARYS acquisition. Investors should watch for Nucynta's ongoing revenue erosion from generic tapentadol, and whether Collegium's ADHD pivot can offset pain-portfolio declines to justify the analyst consensus ~$49 target.
Price Chart
Executive Summary
Collegium reported Q3 2026 net revenue of $216.3M (+3% YoY) and adjusted EPS of $1.96, beating the $1.86 consensus. ADHD portfolio strength (JORNAY PM +24% YoY, AZSTARYS $26.5M in first full quarter) was offset by a 9% decline in adjusted EBITDA to $121.6M and an 18% drop in pain portfolio revenue. Full-year 2026 guidance was reaffirmed.
Key Financial Metrics
Key Facts
- Q3 2026 product revenue $216.3M, up 3% YoY from $209.4M
- Adjusted EPS $1.96 vs consensus $1.86, a beat of 5.4%
- GAAP diluted EPS $0.60 vs $0.84 YoY
- Adjusted EBITDA $121.6M, down 9% from $133.0M YoY
- JORNAY PM revenue $51.9M, up 24% YoY; AZSTARYS $26.5M in first full quarter
- Pain portfolio revenue $138.0M, down 18% YoY; Nucynta franchise down 44%
- Full-year 2026 guidance reaffirmed: product revenue $825-$855M, adjusted EBITDA $445-$470M
- Generated $86.5M cash from operations; ended quarter with $144.8M cash and marketable securities
- Announced $50M accelerated share repurchase program in Q3 2026
Financial Impact
Revenue $216.3M (+3% YoY), adjusted EPS $1.96 beat consensus $1.86 by $0.10
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| JORNAY PM | $51.9M | +24.0% |
| AZSTARYS | $26.5M | Not reported |
| Pain Portfolio | $138.0M | -18.0% |
| Belbuca | $57.7M | -1.0% |
| Xtampza ER | $45.8M | -9.0% |
| Nucynta Franchise | $30.8M | -44.0% |
Risk Factors
- Pain portfolio revenue declining 18% YoY, with Nucynta franchise down 44%
- Adjusted EBITDA down 9% YoY despite revenue growth, reflecting higher operating expenses
- GAAP net income $21.8M vs $31.5M YoY, down 31%
- High debt load ($842.5M term notes, $239.0M convertible notes) relative to $773M market cap
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-070585 |
| Document: collq32026earningspresen.htm | 0001628280-26-070585 |
| Document: coll-20261105.htm | 0001628280-26-070585 |
| Document: 0001628280-26-070585-index-headers.html | 0001628280-26-070585 |
| Document: 0001628280-26-070585-index.html | 0001628280-26-070585 |
| Document: 0001628280-26-070585.txt | 0001628280-26-070585 |
| 8-K Data (Synthetic) | 0001628280-26-070585 |
Track record
24 reports on COLL
1 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +0.28% at T+1 after the Aug 13, 2026 report. 1 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $25.68 Now $25.43 −0.97% settles Nov 17
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $24.47 to $24.81 Now $25.43 +3.92% ▲ +1.39% +0.07% vs SPY
- Nov 9, 20267d ago Institutional Cluster Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 Viewing No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $25.16 to $24.21 Now $25.43 +1.07% ▼ −3.78% −4.09% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $23.80 to $23.68 Now $25.43 +6.85% ▼ −0.50% −0.03% vs SPY
- Oct 29, 202618d ago SC 13G/A Neutral 3/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
- Oct 29, 202618d ago Press Release Neutral 2/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $23.50 to $22.96 Now $25.43 +8.21% ▼ −2.30% −1.78% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers